English

28% GROWTH IN FIRST QUARTER

Report this content

FIRST QUARTER 2012

  • NET SALES amounted to MSEK 30.6 (23.9).
  • OPERATING PROFIT totalled MSEK 8.5 (6.8).
  • PROFIT AFTER TAX amounted to MSEK 6.4 (5.1).
  • PROFIT AFTER TAX PER SHARE was 0.71 SEK (0.55).
  • TOTAL CASH FLOW was MSEK 9.7 (-4.7).

SIGNIFICANT EVENTS DURING THE FIRST QUARTER:

  • Probi signed a distribution agreement with USV Limited of India pertaining to the launch of stomach capsules based on ProbiDigestis, Probi’s product platform for gastrointestinal health.
  • Income in Functional Food increased 6% to MSEK 16.6 (15.7).
  • Income in Consumer Healthcare increased 73% to MSEK 14.4 (8.3).

SIGNIFICANT EVENTS AFTER THE CLOSE OF THE PERIOD:

  • Probi signed an agreement with H.J. Heinz of Australia for the launch of probiotic juice based on ProbiDefendum, Probi’s product platform for the immune system.

CEO’S COMMENTS:

“Q1 income of slightly more than MSEK 30 represents the highest level to date in a single quarter. Our continued strong growth in Consumer Healthcare demonstrates that our strategy to focus resources on developing this market is correct. Our new agreement in the major and expanding Indian market will generate additional opportunities. Combined with this, we are focusing on strengthening our organisation to cope with continued international expansion. We are also very proud of our agreement with Heinz, entailing the launch of a completely new product category in the Australian juice market,” says Michael Oredsson, CEO of Probi.

This type of information is such that Probi AB must disclose in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on 26 April 2012 at 11:30 a.m.

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Michael Oredsson, CEO of Probi, tel: +46 (0)46-286 89 23 or +46 (0)707-18 89 30
e-mail: michael.oredsson@probi.se

ABOUT PROBI

Probi is a leading player in probiotic research and development of effective and well-documented probiotics. The research areas are: the gastrointestinal tract, immune system, metabolic synddrome, as well as stress and recovery. Probi’s customers are leading companies in the Functional Food and Consumer Healthcare segments. Total income for 2011 was MSEK 95.0. Probi’s share is listed on Nasdaq OMX Stockholm, Small Cap. Probi has approximately 4,500 shareholders, Read more on www.probi.se.

Tags:

Q1 Interim report Probi first quarter 2012

Subscribe

Documents & Links